In the current study, among 15 AML patients who received TTCR-C4 post-HCT relapse, we observed indirect evidence supporting anti-leukemic activity but found no survival advantage in patients receiving either EBV- or CMV-specific CD8+ T cells engineered to express TCRC4. The gene discussed is CD8A; the disease is acute myeloid leukemia.